vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and OPTICAL CABLE CORP (OCC). Click either name above to swap in a different company.

OPTICAL CABLE CORP is the larger business by last-quarter revenue ($19.8M vs $19.6M, roughly 1.0× STANDARD BIOTOOLS INC.). OPTICAL CABLE CORP runs the higher net margin — 0.2% vs -177.4%, a 177.7% gap on every dollar of revenue. On growth, OPTICAL CABLE CORP posted the faster year-over-year revenue change (1.8% vs -11.5%). OPTICAL CABLE CORP produced more free cash flow last quarter ($718.8K vs $-23.1M). Over the past eight quarters, OPTICAL CABLE CORP's revenue compounded faster (15.5% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Optical Cable Corporation, headquartered in Roanoke, Virginia, manufactures fiber optical cable. The company's cable is largely used for telecommunications and is sold both in the US and seventy other countries worldwide. OCC also manufactures military land tactical fiber optic cable for the U.S. military.

LAB vs OCC — Head-to-Head

Bigger by revenue
OCC
OCC
1.0× larger
OCC
$19.8M
$19.6M
LAB
Growing faster (revenue YoY)
OCC
OCC
+13.2% gap
OCC
1.8%
-11.5%
LAB
Higher net margin
OCC
OCC
177.7% more per $
OCC
0.2%
-177.4%
LAB
More free cash flow
OCC
OCC
$23.8M more FCF
OCC
$718.8K
$-23.1M
LAB
Faster 2-yr revenue CAGR
OCC
OCC
Annualised
OCC
15.5%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
OCC
OCC
Revenue
$19.6M
$19.8M
Net Profit
$-34.7M
$48.6K
Gross Margin
48.5%
31.9%
Operating Margin
-168.5%
1.4%
Net Margin
-177.4%
0.2%
Revenue YoY
-11.5%
1.8%
Net Profit YoY
-28.8%
-87.0%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
OCC
OCC
Q4 25
$19.8M
Q3 25
$19.6M
$19.9M
Q2 25
$21.8M
$17.5M
Q1 25
$40.8M
$15.7M
Q4 24
$19.5M
Q3 24
$22.1M
$16.2M
Q2 24
$22.5M
$16.1M
Q1 24
$45.5M
$14.9M
Net Profit
LAB
LAB
OCC
OCC
Q4 25
$48.6K
Q3 25
$-34.7M
$301.9K
Q2 25
$-33.5M
$-697.9K
Q1 25
$-26.0M
$-1.1M
Q4 24
$373.5K
Q3 24
$-26.9M
$-1.6M
Q2 24
$-45.7M
$-1.6M
Q1 24
$-32.2M
$-1.4M
Gross Margin
LAB
LAB
OCC
OCC
Q4 25
31.9%
Q3 25
48.5%
31.7%
Q2 25
48.8%
30.4%
Q1 25
48.4%
29.4%
Q4 24
33.5%
Q3 24
54.9%
24.2%
Q2 24
46.1%
25.1%
Q1 24
53.1%
25.0%
Operating Margin
LAB
LAB
OCC
OCC
Q4 25
1.4%
Q3 25
-168.5%
2.8%
Q2 25
-118.1%
-2.4%
Q1 25
-80.8%
-5.4%
Q4 24
3.4%
Q3 24
-120.9%
-8.2%
Q2 24
-134.5%
-8.1%
Q1 24
-132.2%
-9.4%
Net Margin
LAB
LAB
OCC
OCC
Q4 25
0.2%
Q3 25
-177.4%
1.5%
Q2 25
-153.7%
-4.0%
Q1 25
-63.8%
-7.0%
Q4 24
1.9%
Q3 24
-122.0%
-9.6%
Q2 24
-203.3%
-9.9%
Q1 24
-70.6%
-9.6%
EPS (diluted)
LAB
LAB
OCC
OCC
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
OCC
OCC
Cash + ST InvestmentsLiquidity on hand
$129.4M
$237.5K
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$16.5M
Total Assets
$539.6M
$40.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
OCC
OCC
Q4 25
$237.5K
Q3 25
$129.4M
$421.4K
Q2 25
$158.6M
$894.3K
Q1 25
$150.9M
$128.3K
Q4 24
$244.2K
Q3 24
$210.6M
$796.7K
Q2 24
$269.8M
$1.1M
Q1 24
$287.1M
$221.0K
Total Debt
LAB
LAB
OCC
OCC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
OCC
OCC
Q4 25
$16.5M
Q3 25
$399.7M
$18.2M
Q2 25
$424.5M
$19.1M
Q1 25
$454.6M
$19.7M
Q4 24
$20.8M
Q3 24
$489.3M
$20.4M
Q2 24
$510.3M
$21.8M
Q1 24
$577.3M
$23.3M
Total Assets
LAB
LAB
OCC
OCC
Q4 25
$40.1M
Q3 25
$539.6M
$40.2M
Q2 25
$557.0M
$39.1M
Q1 25
$579.6M
$37.8M
Q4 24
$40.4M
Q3 24
$681.5M
$37.6M
Q2 24
$708.7M
$39.9M
Q1 24
$777.7M
$40.5M
Debt / Equity
LAB
LAB
OCC
OCC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
OCC
OCC
Operating Cash FlowLast quarter
$-22.2M
$797.3K
Free Cash FlowOCF − Capex
$-23.1M
$718.8K
FCF MarginFCF / Revenue
-118.1%
3.6%
Capex IntensityCapex / Revenue
4.5%
0.4%
Cash ConversionOCF / Net Profit
16.40×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$1.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
OCC
OCC
Q4 25
$797.3K
Q3 25
$-22.2M
$-2.2M
Q2 25
$-20.7M
$141.4K
Q1 25
$-30.3M
$2.7M
Q4 24
$-1.5M
Q3 24
$-27.9M
$552.4K
Q2 24
$-39.0M
$373.7K
Q1 24
$-62.5M
$-261.1K
Free Cash Flow
LAB
LAB
OCC
OCC
Q4 25
$718.8K
Q3 25
$-23.1M
$-2.3M
Q2 25
$-22.6M
$73.4K
Q1 25
$-35.3M
$2.6M
Q4 24
$-1.6M
Q3 24
$-30.1M
$475.2K
Q2 24
$-41.0M
$218.2K
Q1 24
$-63.3M
$-341.5K
FCF Margin
LAB
LAB
OCC
OCC
Q4 25
3.6%
Q3 25
-118.1%
-11.4%
Q2 25
-103.6%
0.4%
Q1 25
-86.6%
16.5%
Q4 24
-8.1%
Q3 24
-136.4%
2.9%
Q2 24
-182.2%
1.4%
Q1 24
-138.9%
-2.3%
Capex Intensity
LAB
LAB
OCC
OCC
Q4 25
0.4%
Q3 25
4.5%
0.4%
Q2 25
8.7%
0.4%
Q1 25
12.4%
0.5%
Q4 24
0.3%
Q3 24
10.2%
0.5%
Q2 24
8.6%
1.0%
Q1 24
1.7%
0.5%
Cash Conversion
LAB
LAB
OCC
OCC
Q4 25
16.40×
Q3 25
-7.29×
Q2 25
Q1 25
Q4 24
-4.08×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

OCC
OCC

Segment breakdown not available.

Related Comparisons